Last reviewed · How we verify
NCT04486248
Comparison of Magnetic Resonance Techniques for the Measurement of Cerebral Blood Perfusion
trial in Healthy in 30 participants. Completed in 31 December 2022.
24 February 2020
Quick facts
| Lead sponsor | Barcelonabeta Brain Research Center, Pasqual Maragall Foundation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 9 October 2019 |
| Primary completion | 24 February 2020 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Spain |
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Who can join
18 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this project, we aim at implementing a te-ASL sequence and to compare it to two reference ASL sequences with a fixed PLD on healthy individuals. On the one hand, the te-ASL sequence will be compared against a 3D pCASL with a PLD of 1800 ms, as the current reference according the Consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. On the other, as the implemented te-ASL sequence will have a 2D readout, it will also be compared to a 2D pCASL ASL sequence with the same PLD, in order to be able to disentangle differences due to the dynamic PLD scheme from those arising from the different read-out schemes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04486248
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Barcelonabeta Brain Research Center, Pasqual Maragall Foundation trials
Trials by the same sponsor.
- NCT07521722 — DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community · not yet recruiting
- NCT05624632 — Cognitive Remote Assessment Using FLAME (CRA-FLAME) · enrolling by invitation
- NCT04935372 — β-AARC: Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline · active not recruiting
- NCT04482660 — Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population · NA · enrolling by invitation
- NCT04932473 — ALFAsleep: Exploring Cognitive and Biological Correlates of Sleep Quality and Their Potential Links With Alzheimer's Dis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04486248 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
- Last refreshed: 31 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04486248.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing